### Fiscal Year 2021 Duchenne Muscular Dystrophy Research Program (DMDRP)

**Reference Table of Award Mechanisms and Submission Requirements**

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Idea Development Award           | **Established Investigators:** Independent investigators at or above the level of Assistant Professor (or equivalent); **or** **New Investigators:** Investigators that meet the following criteria by the application submission deadline date:  
  - Have not previously received a DMDRP Idea Development Award  
  - Are within 10 years of first faculty appointment (or equivalent) | • Supports the development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes.  
  • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. *Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged.*  
  • Preliminary data required.  
  • Clinical trials or applications including a clinical trial aim are **not allowed**. | • Maximum funding of $350,000 in direct costs (plus indirect costs).  
  • Maximum period of performance is 2 years. | Pre-Application:  
  August 11, 2021  
  5:00 p.m. Eastern time  
  Preproposals are required; application submission is by invitation only.  
  Application:  
  December 1, 2021  
  11:59 p.m. Eastern time |
| Translational Research Award     | Investigators at or above the level of Assistant Professor (or equivalent)   | • Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.  
  • Research projects investigating therapies that will be efficacious across the life-span, particularly in adolescents and adults are strongly encouraged.  
  • Preliminary data required.  
  • Clinical trials are allowed | • Maximum funding of $1,300,000 in direct costs (plus indirect costs).  
  • Maximum period of performance is 3 years | Pre-Application:  
  August 11, 2021  
  5:00 p.m. Eastern time  
  Preproposals are required; application submission is by invitation only.  
  Application:  
  December 1, 2021  
  11:59 p.m. Eastern time |